Separate names with a comma.
DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial...
Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout...
Today's dip might be the last low price here. Going up.... very very soon.
Institute for Integrative Therapies Selected as Clinical Trial Site for COMPASS Pathways’ Psilocybin Treatment for PTSD...
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts...
Psychedelics on the cusp of market breakthrough as clinical, policy support grow...
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights...
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin...
COMPASS Pathways investor presentation August 2026 https://s204.q4cdn.com/927483861/files/doc_presentation/2026/07/FINAL_CMPS_IR-Deck_AUG2026.pdf
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights August 5, 2026...
Three potential takeover targets in psychedelics https://www.pharmavoice.com/news/three-potential-takeover-targets-psychedelics-drug/826887/
Unlocking the Next Step in Compass’ Journey https://www.linkedin.com/pulse/unlocking-next-step-compass-journey-kabir-nath-d2zxc/
I was ok with this. I didn't get in at IPO, but DFTX and CMPS will go at it alone and become very expensive to be bought out.
Big Pharma wants to sell you psychedelic drugs https://spectator.com/article/big-pharma-wants-to-sell-you-psychedelic-drugs/?edition=us
Wells Fargo sees psychedelics market reaching $11B by 2035...
